BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tie J, Gibbs P, Lipton L, Christie M, Jorissen RN, Burgess AW, Croxford M, Jones I, Langland R, Kosmider S, McKay D, Bollag G, Nolop K, Sieber OM, Desai J. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation. Int J Cancer. 2011;128:2075-2084. [PMID: 20635392 DOI: 10.1002/ijc.25555] [Cited by in Crossref: 141] [Cited by in F6Publishing: 134] [Article Influence: 12.8] [Reference Citation Analysis]
Number Citing Articles
1 Kim JH, Kang GH. Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer. World J Gastroenterol 2014; 20(15): 4230-4243 [PMID: 24764661 DOI: 10.3748/wjg.v20.i15.4230] [Cited by in CrossRef: 58] [Cited by in F6Publishing: 56] [Article Influence: 7.3] [Reference Citation Analysis]
2 Cheng HH, Lin JK, Chen WS, Jiang JK, Yang SH, Chang SC. Clinical significance of the BRAFV600E mutation in Asian patients with colorectal cancer. Int J Colorectal Dis. 2018;33:1173-1181. [PMID: 29869121 DOI: 10.1007/s00384-018-3095-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
3 Jin Z, Sinicrope FA. Advances in the therapy of BRAFV600E metastatic colorectal cancer. Expert Rev Anticancer Ther 2019;19:823-9. [PMID: 31455117 DOI: 10.1080/14737140.2019.1661778] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Matos P, Gonçalves V, Jordan P. Targeting the serrated pathway of colorectal cancer with mutation in BRAF. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2016;1866:51-63. [DOI: 10.1016/j.bbcan.2016.06.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
5 Matsuo T, Nishizuka SS, Ishida K, Iwaya T, Ikeda M, Wakabayashi G. Analysis of the anti-tumor effect of cetuximab using protein kinetics and mouse xenograft models. BMC Res Notes 2011;4:140. [PMID: 21554739 DOI: 10.1186/1756-0500-4-140] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
6 Gagnière J, Dupré A, Gholami SS, Pezet D, Boerner T, Gönen M, Kingham TP, Allen PJ, Balachandran VP, De Matteo RP, Drebin JA, Yaeger R, Kemeny NE, Jarnagin WR, D’angelica MI. Is Hepatectomy Justified for BRAF Mutant Colorectal Liver Metastases?: A Multi-institutional Analysis of 1497 Patients. Annals of Surgery 2020;271:147-54. [DOI: 10.1097/sla.0000000000002968] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 14.5] [Reference Citation Analysis]
7 Peeters M, Cohn A, Köhne CH, Douillard JY. Panitumumab in combination with cytotoxic chemotherapy for the treatment of metastatic colorectal carcinoma. Clin Colorectal Cancer 2012;11:14-23. [PMID: 21925954 DOI: 10.1016/j.clcc.2011.06.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
8 Wang F, Bai L, Liu TS, Yu YY, He MM, Liu KY, Luo HY, Zhang DS, Jin Y, Wang FH, Wang ZQ, Wang DS, Qiu MZ, Ren C, Li YH, Xu RH. Right-sided colon cancer and left-sided colorectal cancers respond differently to cetuximab. Chin J Cancer 2015;34:384-93. [PMID: 26111811 DOI: 10.1186/s40880-015-0022-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 34] [Article Influence: 2.4] [Reference Citation Analysis]
9 Benedix F, Meyer F, Kube R, Kropf S, Kuester D, Lippert H, Roessner A, Krüger S. Influence of anatomical subsite on the incidence of microsatellite instability, and KRAS and BRAF mutation rates in patients with colon carcinoma. Pathol Res Pract 2012;208:592-7. [PMID: 22898351 DOI: 10.1016/j.prp.2012.07.003] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
10 El-Osta H, Falchook G, Tsimberidou A, Hong D, Naing A, Kim K, Wen S, Janku F, Kurzrock R. BRAF mutations in advanced cancers: clinical characteristics and outcomes. PLoS One 2011;6:e25806. [PMID: 22039425 DOI: 10.1371/journal.pone.0025806] [Cited by in Crossref: 65] [Cited by in F6Publishing: 58] [Article Influence: 5.9] [Reference Citation Analysis]
11 Day F, Muranyi A, Singh S, Shanmugam K, Williams D, Byrne D, Pham K, Palmieri M, Tie J, Grogan T, Gibbs P, Sieber O, Waring P, Desai J. A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer. Target Oncol 2015;10:99-109. [PMID: 24859797 DOI: 10.1007/s11523-014-0319-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
12 Clarke CN, Kopetz ES. BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies. J Gastrointest Oncol. 2015;6:660-667. [PMID: 26697199 DOI: 10.3978/j.issn.2078-6891.2015.077] [Cited by in F6Publishing: 58] [Reference Citation Analysis]
13 Di Nicolantonio F, Vitiello PP, Marsoni S, Siena S, Tabernero J, Trusolino L, Bernards R, Bardelli A. Precision oncology in metastatic colorectal cancer - from biology to medicine. Nat Rev Clin Oncol 2021;18:506-25. [PMID: 33864051 DOI: 10.1038/s41571-021-00495-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
14 He K, Wang Y, Zhong Y, Pan X, Si L, Lu J. KRAS Codon 12 Mutation is Associated with More Aggressive Invasiveness in Synchronous Metastatic Colorectal Cancer (mCRC): Retrospective Research. Onco Targets Ther 2020;13:12601-13. [PMID: 33335401 DOI: 10.2147/OTT.S279312] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Vemala RNG, Katti SV, Sirohi B, Manikandan D, Nandakumar G. Molecular Oncology in Management of Colorectal Cancer. Indian J Surg Oncol 2021;12:169-80. [PMID: 33994743 DOI: 10.1007/s13193-021-01289-6] [Reference Citation Analysis]
16 Bozzao C, Varvara D, Piglionica M, Bagnulo R, Forte G, Patruno M, Russo S, Piscitelli D, Stella A, Resta N. Survey of KRAS, BRAF and PIK3CA mutational status in 209 consecutive Italian colorectal cancer patients. Int J Biol Markers 2012;27:366-74. [DOI: 10.5301/jbm.2012.9765] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
17 Ahn DH, Goldberg RM. Colorectal clinical trials: what is on the horizon? Future Oncol 2016;12:525-31. [PMID: 26777152 DOI: 10.2217/fon.15.327] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
18 Coulson R. Molecular Profiling in Resectable Colorectal Liver Metastases: The Role of KRAS Mutation Status in Assessing Prognosis in the Preoperative Setting. J Adv Pract Oncol 2015;6:470-4. [PMID: 27069739 DOI: 10.6004/jadpro.2015.6.5.7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
19 Johnson B, Jin Z, Truty MJ, Smoot RL, Nagorney DM, Kendrick ML, Kipp BR, Grothey A. Impact of Metastasectomy in the Multimodality Approach for BRAF V600E Metastatic Colorectal Cancer: The Mayo Clinic Experience. Oncologist 2018;23:128-34. [PMID: 28904173 DOI: 10.1634/theoncologist.2017-0230] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
20 Sorbye H, Dragomir A, Sundström M, Pfeiffer P, Thunberg U, Bergfors M, Aasebø K, Eide GE, Ponten F, Qvortrup C, Glimelius B. High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort. PLoS One 2015;10:e0131046. [PMID: 26121270 DOI: 10.1371/journal.pone.0131046] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 7.4] [Reference Citation Analysis]
21 Heinemann V, Douillard JY, Ducreux M, Peeters M. Targeted therapy in metastatic colorectal cancer -- an example of personalised medicine in action. Cancer Treat Rev 2013;39:592-601. [PMID: 23375249 DOI: 10.1016/j.ctrv.2012.12.011] [Cited by in Crossref: 85] [Cited by in F6Publishing: 77] [Article Influence: 9.4] [Reference Citation Analysis]
22 Karapetis CS, Maru D, Waring P, Tie J, Michael MZ. Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer. Expert Rev Mol Diagn 2015;15:1033-48. [PMID: 26166616 DOI: 10.1586/14737159.2015.1052797] [Reference Citation Analysis]
23 Wang X, Wei Q, Gao J, Li J, Li J, Gong J, Li Y, Shen L. Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study. Chin J Cancer 2017;36:81. [PMID: 29037218 DOI: 10.1186/s40880-017-0247-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
24 Zekri J, Baghdadi MA, Alardati H, Khallaf H, Kabanja JH. Evaluation of the Idylla KRAS and NRAS mutation test in colorectal cancer tissue. Experimental and Molecular Pathology 2019;110:104270. [DOI: 10.1016/j.yexmp.2019.104270] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
25 Li D, Fu Q, Li M, Li J, Yin C, Zhao J, Li F. Primary tumor site and anti-EGFR monoclonal antibody benefit in metastatic colorectal cancer: a meta-analysis. Future Oncol. 2017;13:1115-1127. [PMID: 28110551 DOI: 10.2217/fon-2016-0468] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
26 Atreya CE, Greene C, McWhirter RM, Ikram NS, Allen IE, Van Loon K, Venook AP, Yeh BM, Behr SC. Differential Radiographic Appearance of BRAF V600E-Mutant Metastatic Colorectal Cancer in Patients Matched by Primary Tumor Location. J Natl Compr Canc Netw 2016;14:1536-43. [PMID: 27956538 DOI: 10.6004/jnccn.2016.0165] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
27 Kayhanian H, Goode E, Sclafani F, Ang JE, Gerlinger M, Gonzalez de Castro D, Shepherd S, Peckitt C, Rao S, Watkins D, Chau I, Cunningham D, Starling N. Treatment and Survival Outcome of BRAF-Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case-Control Study. Clin Colorectal Cancer. 2018;17:e69-e76. [PMID: 29129559 DOI: 10.1016/j.clcc.2017.10.006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
28 Cortellini A, Cannita K, Parisi A, Lanfiuti Baldi P, Venditti O, D'Orazio C, Dal Mas A, Calvisi G, Giordano AV, Vicentini V, Vicentini R, Felicioni L, Marchetti A, Buttitta F, Russo A, Ficorella C. Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice. Onco Targets Ther 2019;12:2159-70. [PMID: 30988620 DOI: 10.2147/OTT.S194745] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
29 Jorissen RN, Christie M, Mouradov D, Sakthianandeswaren A, Li S, Love C, Xu ZZ, Molloy PL, Jones IT, McLaughlin S, Ward RL, Hawkins NJ, Ruszkiewicz AR, Moore J, Burgess AW, Busam D, Zhao Q, Strausberg RL, Lipton L, Desai J, Gibbs P, Sieber OM. Wild-type APC predicts poor prognosis in microsatellite-stable proximal colon cancer. Br J Cancer. 2015;113:979-988. [PMID: 26305864 DOI: 10.1038/bjc.2015.296] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
30 Garbe C, Eigentler TK. Vemurafenib. Recent Results Cancer Res 2018;211:77-89. [PMID: 30069761 DOI: 10.1007/978-3-319-91442-8_6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
31 Geramizadeh B. Molecular Biomarkers of Colorectal Cancer: A Review of Published Articles From Iran. Ann Colorectal Res 2015;3. [DOI: 10.17795/acr-30100] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
32 Boisen MK, Johansen JS, Dehlendorff C, Larsen JS, Østerlind K, Hansen J, Nielsen SE, Pfeiffer P, Tarpgaard LS, Holländer NH, Keldsen N, Hansen TF, Jensen BB, Jensen BV. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer. Ann Oncol 2013;24:2554-9. [PMID: 23864097 DOI: 10.1093/annonc/mdt253] [Cited by in Crossref: 59] [Cited by in F6Publishing: 61] [Article Influence: 6.6] [Reference Citation Analysis]
33 Ishida H, Yamaguchi T, Chiba K, Iijima T, Horiguchi SI. A case report of ascending colon adenosquamous carcinoma with BRAF V600E mutation. Int Cancer Conf J 2017;6:93-7. [PMID: 31149479 DOI: 10.1007/s13691-017-0283-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
34 Tran B, Dancey JE, Kamel-reid S, Mcpherson JD, Bedard PL, Brown AM, Zhang T, Shaw P, Onetto N, Stein L, Hudson TJ, Neel BG, Siu LL. Cancer Genomics: Technology, Discovery, and Translation. JCO 2012;30:647-60. [DOI: 10.1200/jco.2011.39.2316] [Cited by in Crossref: 127] [Cited by in F6Publishing: 58] [Article Influence: 12.7] [Reference Citation Analysis]
35 Park R, Lopes L, Lee S, Riano I, Saeed A. The prognostic and predictive impact of BRAF mutations in deficient mismatch repair/microsatellite instability-high colorectal cancer: systematic review/meta-analysis. Future Oncol 2021;17:4221-31. [PMID: 34323124 DOI: 10.2217/fon-2021-0552] [Reference Citation Analysis]
36 Sveen A, Kopetz S, Lothe RA. Biomarker-guided therapy for colorectal cancer: strength in complexity. Nat Rev Clin Oncol 2020;17:11-32. [PMID: 31289352 DOI: 10.1038/s41571-019-0241-1] [Cited by in Crossref: 67] [Cited by in F6Publishing: 68] [Article Influence: 22.3] [Reference Citation Analysis]
37 Nakayama I, Hirota T, Shinozaki E. BRAF Mutation in Colorectal Cancers: From Prognostic Marker to Targetable Mutation. Cancers (Basel) 2020;12:E3236. [PMID: 33152998 DOI: 10.3390/cancers12113236] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
38 Hocking CM, Price TJ. Panitumumab in the management of patients with KRAS wild-type metastatic colorectal cancer. Therap Adv Gastroenterol. 2014;7:20-37. [PMID: 24381645 DOI: 10.1177/1756283x13498660] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
39 Corcoran RB. New therapeutic strategies for BRAF mutant colorectal cancers. J Gastrointest Oncol 2015;6:650-9. [PMID: 26697198 DOI: 10.3978/j.issn.2078-6891.2015.076] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
40 Garcia-Carbonero N, Martinez-Useros J, Li W, Orta A, Perez N, Carames C, Hernandez T, Moreno I, Serrano G, Garcia-Foncillas J. KRAS and BRAF Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study. Cells 2020;9:E219. [PMID: 31952366 DOI: 10.3390/cells9010219] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
41 Sammarco G, Gallo G, Vescio G, Picciariello A, De Paola G, Trompetto M, Currò G, Ammendola M. Mast Cells, microRNAs and Others: The Role of Translational Research on Colorectal Cancer in the Forthcoming Era of Precision Medicine. J Clin Med 2020;9:E2852. [PMID: 32899322 DOI: 10.3390/jcm9092852] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
42 Dinami R, Porru M, Amoreo CA, Sperduti I, Mottolese M, Buglioni S, Marinelli D, Maugeri-Saccà M, Sacconi A, Blandino G, Leonetti C, Di Rocco G, Verdina A, Spinella F, Fiorentino F, Ciliberto G, Biroccio A, Zizza P. TRF2 and VEGF-A: an unknown relationship with prognostic impact on survival of colorectal cancer patients. J Exp Clin Cancer Res 2020;39:111. [PMID: 32539869 DOI: 10.1186/s13046-020-01612-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
43 Ursem C, Atreya CE, Van Loon K. Emerging treatment options for BRAF-mutant colorectal cancer. Gastrointest Cancer. 2018;8:13-23. [PMID: 29628780 DOI: 10.2147/gictt.s125940] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]
44 Wang J, Shen J, Huang C, Cao M, Shen L. Clinicopathological Significance of BRAFV600E Mutation in Colorectal Cancer: An Updated Meta-Analysis. J Cancer. 2019;10:2332-2341. [PMID: 31258736 DOI: 10.7150/jca.30789] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
45 Chen D, Huang JF, Liu K, Zhang LQ, Yang Z, Chuai ZR, Wang YX, Shi DC, Huang Q, Fu WL. BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis. PLoS One. 2014;9:e90607. [PMID: 24594804 DOI: 10.1371/journal.pone.0090607] [Cited by in Crossref: 78] [Cited by in F6Publishing: 75] [Article Influence: 9.8] [Reference Citation Analysis]
46 Kinnersley B, Migliorini G, Broderick P, Whiffin N, Dobbins SE, Casey G, Hopper J, Sieber O, Lipton L, Kerr DJ. The TERT variant rs2736100 is associated with colorectal cancer risk. Br J Cancer. 2012;107:1001-1008. [PMID: 22878375 DOI: 10.1038/bjc.2012.329] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 4.5] [Reference Citation Analysis]
47 Saravani K, Salarzaei M, Parooie F. Effect of KRAS and BRAF mutations in metastatic colorectal cancer patients: A systematic review and meta-analysis based on tumor sidedness and KRAS subtypes. Hum Antibodies 2021. [PMID: 34334388 DOI: 10.3233/HAB-210451] [Reference Citation Analysis]
48 Clarke SJ, Karapetis CS, Gibbs P, Pavlakis N, Desai J, Michael M, Tebbutt NC, Price TJ, Tabernero J. Overview of biomarkers in metastatic colorectal cancer: tumour, blood and patient-related factors. Crit Rev Oncol Hematol 2013;85:121-35. [PMID: 22762963 DOI: 10.1016/j.critrevonc.2012.06.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
49 Cremolini C, Di Bartolomeo M, Amatu A, Antoniotti C, Moretto R, Berenato R, Perrone F, Tamborini E, Aprile G, Lonardi S. BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. Ann Oncol. 2015;26:2092-2097. [PMID: 26153495 DOI: 10.1093/annonc/mdv290] [Cited by in Crossref: 98] [Cited by in F6Publishing: 89] [Article Influence: 14.0] [Reference Citation Analysis]
50 Hsieh YC, Chang TK, Su WC, Huang CW, Tsai HL, Chen YC, Li CC, Chen PJ, Yin TC, Ma CJ, Wang JY. UGT1A1 Polymorphism for Irinotecan Dose Escalation in Patients with BRAF-Mutated Metastatic Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI. J Oncol 2021;2021:6686517. [PMID: 33777142 DOI: 10.1155/2021/6686517] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Cerrito MG, Grassilli E. Identifying Novel Actionable Targets in Colon Cancer. Biomedicines 2021;9:579. [PMID: 34065438 DOI: 10.3390/biomedicines9050579] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Loupakis F, Cremolini C, Salvatore L, Masi G, Sensi E, Schirripa M, Michelucci A, Pfanner E, Brunetti I, Lupi C, Antoniotti C, Bergamo F, Lonardi S, Zagonel V, Simi P, Fontanini G, Falcone A. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. Eur J Cancer. 2014;50:57-63. [PMID: 24138831 DOI: 10.1016/j.ejca.2013.08.024] [Cited by in Crossref: 123] [Cited by in F6Publishing: 107] [Article Influence: 13.7] [Reference Citation Analysis]
53 Mineur L, François E, Plassot C, Phelip JM, Miglianico L, Dourthe LM, Bonichon N, Moreau L, Guimbaud R, Smith D, Achille E, Hervé R, Bons JM, Remy S, Faroux R, Villing AL, Mahamat A, Rabbia I, Soulié P, Baumgaertner I, Mathé N, Vazquez L, Boustany R. PREMIUM: A French prospective multicenter observational study of factors impacting on efficacy and compliance to cetuximab treatment in first-line KRAS wild-type metastatic colorectal cancer. PLoS One 2020;15:e0243997. [PMID: 33347495 DOI: 10.1371/journal.pone.0243997] [Reference Citation Analysis]
54 Tie J, Desai J. Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies. Target Oncol. 2015;10:179-188. [PMID: 25119972 DOI: 10.1007/s11523-014-0330-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
55 Gau L, Ribeiro M, Pereira B, Poirot K, Dupré A, Pezet D, Gagnière J. Impact of BRAF mutations on clinical outcomes following liver surgery for colorectal liver metastases: An updated meta-analysis. Eur J Surg Oncol 2021:S0748-7983(21)00534-5. [PMID: 34099355 DOI: 10.1016/j.ejso.2021.05.039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Hanna MC, Go C, Roden C, Jones RT, Pochanard P, Javed AY, Javed A, Mondal C, Palescandolo E, Van Hummelen P. Colorectal cancers from distinct ancestral populations show variations in BRAF mutation frequency. PLoS One. 2013;8:e74950. [PMID: 24066160 DOI: 10.1371/journal.pone.0074950] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis]
57 Jensen CE, Villanueva JY, Loaiza-Bonilla A. Differences in overall survival and mutation prevalence between right- and left-sided colorectal adenocarcinoma. J Gastrointest Oncol 2018;9:778-84. [PMID: 30505575 DOI: 10.21037/jgo.2018.06.10] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
58 Hong MK, Sapre N, Phal PM, Macintyre G, Chin X, Pedersen JS, Ryan A, Kerger M, Costello AJ, Corcoran NM, Hovens CM. Percutaneous image-guided biopsy of prostate cancer metastases yields samples suitable for genomics and personalised oncology. Clin Exp Metastasis 2014;31:159-67. [PMID: 24085599 DOI: 10.1007/s10585-013-9617-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
59 Sclafani F, Gullo G, Sheahan K, Crown J. BRAF mutations in melanoma and colorectal cancer: a single oncogenic mutation with different tumour phenotypes and clinical implications. Crit Rev Oncol Hematol. 2013;87:55-68. [PMID: 23246082 DOI: 10.1016/j.critrevonc.2012.11.003] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 3.8] [Reference Citation Analysis]
60 Tanaka K, Yoshida Y, Yamada T, Hayashi T, Shimaoka H, Yoshimura F, Kajitani R, Munechika T, Matsumoto Y, Nagano H, Komono A, Sakamoto R, Nakashima R, Aisu N, Yoshimatsu G, Hasegawa S. Oncological evaluation in the perioperative period using cfDNA with BRAF V600E mutation in patients with colorectal cancer. Sci Rep 2021;11:13263. [PMID: 34168268 DOI: 10.1038/s41598-021-92795-8] [Reference Citation Analysis]
61 Safaee Ardekani G, Jafarnejad SM, Tan L, Saeedi A, Li G. The prognostic value of BRAF mutation in colorectal cancer and melanoma: A systematic review and meta-analysis. PLoS One. 2012;7:e47054. [PMID: 23056577 DOI: 10.1371/journal.pone.0047054] [Cited by in Crossref: 134] [Cited by in F6Publishing: 134] [Article Influence: 13.4] [Reference Citation Analysis]
62 Ye JX, Liu Y, Qin Y, Zhong HH, Yi WN, Shi XY. KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients. World J Gastroenterol 2015; 21(5): 1595-1605 [PMID: 25663779 DOI: 10.3748/wjg.v21.i5.1595] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
63 Schirripa M, Lenz HJ. Biomarker in Colorectal Cancer. Cancer J 2016;22:156-64. [PMID: 27341592 DOI: 10.1097/PPO.0000000000000190] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 4.4] [Reference Citation Analysis]
64 Osumi H, Shinozaki E, Wakatsuki T, Suenaga M, Ichimura T, Ogura M, Takahari D, Ooki A, Suzuki T, Ota Y, Nakayama I, Chin K, Miki Y, Yamaguchi K. Non-V600E BRAF mutations and EGFR signaling pathway in colorectal cancer. Int J Cancer 2019;145:2488-95. [PMID: 30963570 DOI: 10.1002/ijc.32320] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
65 Huijberts SC, van Geel RM, Bernards R, Beijnen JH, Steeghs N. Encorafenib, binimetinib and cetuximab combined therapy for patients with BRAFV600E mutant metastatic colorectal cancer. Future Oncol 2020;16:161-73. [PMID: 32027186 DOI: 10.2217/fon-2019-0748] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
66 Ahn DH, Ciombor KK, Mikhail S, Bekaii-Saab T. Genomic diversity of colorectal cancer: Changing landscape and emerging targets. World J Gastroenterol 2016; 22(25): 5668-5677 [PMID: 27433082 DOI: 10.3748/wjg.v22.i25.5668] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
67 Ishimaru K, Kawai K, Nozawa H, Sasaki K, Murono K, Emoto S, Ishii H, Anzai H, Sonoda H, Yamauchi S, Sugihara K, Ishihara S; And other members of the University of Tokyo Study Group. Hazard function analysis of metastatic recurrence after colorectal cancer surgery-A nationwide retrospective study. J Surg Oncol 2021;123:1015-22. [PMID: 33444465 DOI: 10.1002/jso.26378] [Reference Citation Analysis]
68 Personeni N, Smiroldo V, Giunta EF, Prete MG, Rimassa L, Bregni G, Sclafani F. Tackling Refractory Metastatic Colorectal Cancer: Future Perspectives. Cancers (Basel) 2021;13:4506. [PMID: 34572729 DOI: 10.3390/cancers13184506] [Reference Citation Analysis]
69 Roma C, Rachiglio AM, Pasquale R, Fenizia F, Iannaccone A, Tatangelo F, Antinolfi G, Parrella P, Graziano P, Sabatino L, Colantuoni V, Botti G, Maiello E, Normanno N. BRAF V600E mutation in metastatic colorectal cancer: Methods of detection and correlation with clinical and pathologic features. Cancer Biol Ther 2016;17:840-8. [PMID: 27261210 DOI: 10.1080/15384047.2016.1195048] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
70 In 't Veld SGJG, Duong KN, Snel M, Witteveen A, Beumer IJ, Delahaye LJMJ, Wehkamp D, Bernards R, Glas AM, Tian S. A Computational Workflow Translates a 58-Gene Signature to a Formalin-Fixed, Paraffin-Embedded Sample-Based Companion Diagnostic for Personalized Treatment of the BRAF-Mutation-Like Subtype of Colorectal Cancers. High Throughput 2017;6:E16. [PMID: 29479053 DOI: 10.3390/ht6040016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
71 Battaglin F, Puccini A, Naseem M, Schirripa M, Berger MD, Tokunaga R, McSkane M, Khoukaz T, Soni S, Zhang W, Lenz HJ. Pharmacogenomics in colorectal cancer: current role in clinical practice and future perspectives. J Cancer Metastasis Treat 2018;4:12. [PMID: 34532592 DOI: 10.20517/2394-4722.2018.04] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
72 Vecchione L, Gambino V, Raaijmakers J, Schlicker A, Fumagalli A, Russo M, Villanueva A, Beerling E, Bartolini A, Mollevi DG, El-Murr N, Chiron M, Calvet L, Nicolazzi C, Combeau C, Henry C, Simon IM, Tian S, in 't Veld S, D'ario G, Mainardi S, Beijersbergen RL, Lieftink C, Linn S, Rumpf-Kienzl C, Delorenzi M, Wessels L, Salazar R, Di Nicolantonio F, Bardelli A, van Rheenen J, Medema RH, Tejpar S, Bernards R. A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility. Cell 2016;165:317-30. [PMID: 27058664 DOI: 10.1016/j.cell.2016.02.059] [Cited by in Crossref: 52] [Cited by in F6Publishing: 43] [Article Influence: 8.7] [Reference Citation Analysis]
73 Tomlinson IP, Carvajal-Carmona LG, Dobbins SE, Tenesa A, Jones AM, Howarth K, Palles C, Broderick P, Jaeger EE, Farrington S, Lewis A, Prendergast JG, Pittman AM, Theodoratou E, Olver B, Walker M, Penegar S, Barclay E, Whiffin N, Martin L, Ballereau S, Lloyd A, Gorman M, Lubbe S, Howie B, Marchini J, Ruiz-Ponte C, Fernandez-Rozadilla C, Castells A, Carracedo A, Castellvi-Bel S, Duggan D, Conti D, Cazier JB, Campbell H, Sieber O, Lipton L, Gibbs P, Martin NG, Montgomery GW, Young J, Baird PN, Gallinger S, Newcomb P, Hopper J, Jenkins MA, Aaltonen LA, Kerr DJ, Cheadle J, Pharoah P, Casey G, Houlston RS, Dunlop MG; COGENT Consortium., CORGI Collaborators., EPICOLON Consortium. Multiple common susceptibility variants near BMP pathway loci GREM1, BMP4, and BMP2 explain part of the missing heritability of colorectal cancer. PLoS Genet 2011;7:e1002105. [PMID: 21655089 DOI: 10.1371/journal.pgen.1002105] [Cited by in Crossref: 159] [Cited by in F6Publishing: 156] [Article Influence: 14.5] [Reference Citation Analysis]
74 Krol LC, ‘t Hart NA, Methorst N, Knol AJ, Prinsen C, Boers JE. Concordance in KRAS and BRAF mutations in endoscopic biopsy samples and resection specimens of colorectal adenocarcinoma. Eur J Cancer. 2012;48:1108-1115. [PMID: 22446020 DOI: 10.1016/j.ejca.2012.02.054] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
75 Lipton L, Christie M, Sieber O. Predictive and Prognostic Biomarkers for Colorectal Cancer. In: Pfeffer U, editor. Cancer Genomics. Dordrecht: Springer Netherlands; 2013. pp. 131-62. [DOI: 10.1007/978-94-007-5842-1_5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
76 Zonnur S, Erbersdobler A, Schneider B. EGFR and BRAF mutations in inverted sinonasal papilloma - a more complex landscape? Virchows Arch 2021;478:915-24. [PMID: 33048186 DOI: 10.1007/s00428-020-02945-y] [Reference Citation Analysis]
77 Guarini C, Grassi T, Pezzicoli G, Porta C. Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer. Int J Mol Sci 2021;22:6813. [PMID: 34202896 DOI: 10.3390/ijms22136813] [Reference Citation Analysis]
78 Venderbosch S, Nagtegaal ID, Maughan TS, Smith CG, Cheadle JP, Fisher D, Kaplan R, Quirke P, Seymour MT, Richman SD, Meijer GA, Ylstra B, Heideman DA, de Haan AF, Punt CJ, Koopman M. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res 2014;20:5322-30. [PMID: 25139339 DOI: 10.1158/1078-0432.CCR-14-0332] [Cited by in Crossref: 326] [Cited by in F6Publishing: 164] [Article Influence: 40.8] [Reference Citation Analysis]
79 Sastre J, Orden V, Martínez A, Bando I, Balbín M, Bellosillo B, Palanca S, Peligros Gomez MI, Mediero B, Llovet P, Moral VM, Viéitez JM, García-Alfonso P, Calle SG, Ortiz-Morales MJ, Salud A, Quintero G, Lopez C, Díaz-Rubio E, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD). Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected. Clin Colorectal Cancer 2020;19:e110-6. [PMID: 32278676 DOI: 10.1016/j.clcc.2020.02.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
80 Burge M, Price T, Karapetis CS. First-line therapy for metastatic colorectal cancer: Current perspectives and future directions. Asia Pac J Clin Oncol 2019;15 Suppl 1:3-14. [PMID: 30758881 DOI: 10.1111/ajco.13119] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
81 Lai E, Pretta A, Impera V, Mariani S, Giampieri R, Casula L, Pusceddu V, Coni P, Fanni D, Puzzoni M, Demurtas L, Ziranu P, Faa G, Scartozzi M. BRAF-mutant colorectal cancer, a different breed evolving. Expert Review of Molecular Diagnostics 2018;18:499-512. [DOI: 10.1080/14737159.2018.1470928] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
82 Pfeiffer P, Köhne CH, Qvortrup C. The changing face of treatment for metastatic colorectal cancer. Expert Rev Anticancer Ther 2019;19:61-70. [PMID: 30381969 DOI: 10.1080/14737140.2019.1543593] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
83 Ros J, Baraibar I, Sardo E, Mulet N, Salvà F, Argilés G, Martini G, Ciardiello D, Cuadra JL, Tabernero J, Élez E. BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer. Ther Adv Med Oncol 2021;13:1758835921992974. [PMID: 33747149 DOI: 10.1177/1758835921992974] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
84 Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, Mezi S, Tomasello G, Ronzoni M, Zaniboni A, Tonini G, Carlomagno C, Allegrini G, Chiara S, D'Amico M, Granetto C, Cazzaniga M, Boni L, Fontanini G, Falcone A. FOLFOXIRI plus bevacizumab vs FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16:1306-1315. [PMID: 26338525 DOI: 10.1016/s1470-2045(15)00122-9] [Cited by in Crossref: 478] [Cited by in F6Publishing: 243] [Article Influence: 68.3] [Reference Citation Analysis]
85 Tayeb BA, Pringle HJ. The Sensitivity and Specificity of Novel Primers for Detection of BRAFV600E Mutation. Asian Pac J Cancer Prev 2020;21:3191-8. [PMID: 33247675 DOI: 10.31557/APJCP.2020.21.11.3191] [Reference Citation Analysis]
86 Zhang Z, Wang A, Tang X, Chen Y, Tang E, Jiang H. Comparative mutational analysis of distal colon cancer with rectal cancer. Oncol Lett 2020;19:1781-8. [PMID: 32194671 DOI: 10.3892/ol.2020.11269] [Reference Citation Analysis]
87 Djanani A, Eller S, Öfner D, Troppmair J, Maglione M. The Role of BRAF in Metastatic Colorectal Carcinoma-Past, Present, and Future. Int J Mol Sci 2020;21:E9001. [PMID: 33256240 DOI: 10.3390/ijms21239001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
88 Garbe C, Abusaif S, Eigentler TK. Vemurafenib. Recent Results Cancer Res 2014;201:215-25. [PMID: 24756795 DOI: 10.1007/978-3-642-54490-3_13] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
89 Dvorak K, Aggeler B, Palting J, McKelvie P, Ruszkiewicz A, Waring P. Immunohistochemistry with the anti-BRAF V600E (VE1) antibody: impact of pre-analytical conditions and concordance with DNA sequencing in colorectal and papillary thyroid carcinoma. Pathology 2014;46:509-17. [PMID: 25014730 DOI: 10.1097/PAT.0000000000000119] [Cited by in Crossref: 52] [Cited by in F6Publishing: 28] [Article Influence: 8.7] [Reference Citation Analysis]
90 Zhang J, Ji T. Chemotherapeutic drug selectivity between wild-type and mutant BRaf kinases in colon cancer. J Mol Model 2017;23. [DOI: 10.1007/s00894-016-3177-8] [Cited by in Crossref: 5] [Article Influence: 0.8] [Reference Citation Analysis]
91 Sanz-Garcia E, Argiles G, Elez E, Tabernero J. BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives. Ann Oncol. 2017;28:2648-2657. [PMID: 29045527 DOI: 10.1093/annonc/mdx401] [Cited by in Crossref: 100] [Cited by in F6Publishing: 97] [Article Influence: 25.0] [Reference Citation Analysis]
92 Li Y, Li W. BRAF mutation is associated with poor clinicopathological outcomes in colorectal cancer: A meta-analysis. Saudi J Gastroenterol 2017;23:144-9. [PMID: 28611337 DOI: 10.4103/1319-3767.207712] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
93 Schirripa M, Cremolini C, Loupakis F, Morvillo M, Bergamo F, Zoratto F, Salvatore L, Antoniotti C, Marmorino F, Sensi E. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. Int J Cancer. 2015;136:83-90. [PMID: 24806288 DOI: 10.1002/ijc.28955] [Cited by in Crossref: 75] [Cited by in F6Publishing: 73] [Article Influence: 9.4] [Reference Citation Analysis]
94 Ji J, Wang C, Fakih M. Rechallenge With BRAF and anti-EGFR Inhibitors in Patients With Metastatic Colorectal Cancer Harboring BRAF Mutation Who Progressed on Cetuximab and Encorafenib With or Without Binimetinib: A Case Series. Clinical Colorectal Cancer 2021. [DOI: 10.1016/j.clcc.2021.12.001] [Reference Citation Analysis]
95 Fanelli GN, Dal Pozzo CA, Depetris I, Schirripa M, Brignola S, Biason P, Balistreri M, Dal Santo L, Lonardi S, Munari G, Loupakis F, Fassan M. The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer. Cancer Cell Int. 2020;20:30. [PMID: 32015690 DOI: 10.1186/s12935-020-1117-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
96 Guan WL, Qiu MZ, He CY, Yang LQ, Jin Y, Wang ZQ, Li YH, Xu RH, Wang FH. Clinicopathologic Features and Prognosis of BRAF Mutated Colorectal Cancer Patients. Front Oncol 2020;10:563407. [PMID: 33330032 DOI: 10.3389/fonc.2020.563407] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
97 Afrăsânie VA, Marinca MV, Alexa-Stratulat T, Gafton B, Păduraru M, Adavidoaiei AM, Miron L, Rusu C. KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer - practical implications for the clinician. Radiol Oncol 2019;53:265-74. [PMID: 31553708 DOI: 10.2478/raon-2019-0033] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 8.7] [Reference Citation Analysis]
98 Strickler JH, Wu C, Bekaii-Saab T. Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches. Cancer Treat Rev. 2017;60:109-119. [PMID: 28946014 DOI: 10.1016/j.ctrv.2017.08.006] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
99 Yang Y, Wang D, Jin L, Wu G, Bai Z, Wang J, Yao H, Zhang Z. Prognostic value of the combination of microsatellite instability and BRAF mutation in colorectal cancer. Cancer Manag Res 2018;10:3911-29. [PMID: 30310312 DOI: 10.2147/CMAR.S169649] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
100 Voskoboynik M, Bae S, Ananda S, Desai J, Kosmider S, Gibbs P. An initial watch and wait approach is a valid strategy for selected patients with newly diagnosed metastatic colorectal cancer. Ann Oncol. 2012;23:2633-2637. [PMID: 22734008 DOI: 10.1093/annonc/mds184] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
101 Kawakami H, Huang S, Pal K, Dutta SK, Mukhopadhyay D, Sinicrope FA. Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer. Mol Cancer Ther 2016;15:3015-27. [PMID: 27765849 DOI: 10.1158/1535-7163.MCT-16-0017] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 3.2] [Reference Citation Analysis]
102 Park T, Choi C, Choi Y, Suh D. Cost-effectiveness of cetuximab for colorectal cancer. Expert Review of Pharmacoeconomics & Outcomes Research 2016;16:667-77. [DOI: 10.1080/14737167.2016.1245618] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
103 Scartozzi M, Giampieri R, Aprile G, Iacono D, Santini D, dell’Aquila E, Silvestris N, Gnoni A, Bonotto M, Puzzoni M, Demurtas L, Cascinu S. The distinctive molecular, pathological and clinical characteristics of BRAF -mutant colorectal tumors. Expert Review of Molecular Diagnostics 2015;15:979-87. [DOI: 10.1586/14737159.2015.1047346] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
104 Morris V, Overman MJ, Jiang ZQ, Garrett C, Agarwal S, Eng C, Kee B, Fogelman D, Dasari A, Wolff R, Maru D, Kopetz S. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer. 2014;13:164-171. [PMID: 25069797 DOI: 10.1016/j.clcc.2014.06.001] [Cited by in Crossref: 66] [Cited by in F6Publishing: 65] [Article Influence: 8.3] [Reference Citation Analysis]
105 Van Cutsem E, Huijberts S, Grothey A, Yaeger R, Cuyle PJ, Elez E, Fakih M, Montagut C, Peeters M, Yoshino T, Wasan H, Desai J, Ciardiello F, Gollerkeri A, Christy-Bittel J, Maharry K, Sandor V, Schellens JHM, Kopetz S, Tabernero J. Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study. J Clin Oncol 2019;37:1460-9. [PMID: 30892987 DOI: 10.1200/JCO.18.02459] [Cited by in Crossref: 91] [Cited by in F6Publishing: 56] [Article Influence: 30.3] [Reference Citation Analysis]
106 Sánchez-Botet A, Gasa L, Quandt E, Hernández-Ortega S, Jiménez J, Mezquita P, Carrasco-García MÀ, Kron SJ, Vidal A, Villanueva A, Ribeiro MPC, Clotet J. The atypical cyclin CNTD2 promotes colon cancer cell proliferation and migration. Sci Rep 2018;8:11797. [PMID: 30087414 DOI: 10.1038/s41598-018-30307-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
107 Cherri S, Libertini M, Zaniboni A. New drugs for the treatment of metastatic colorectal cancer. World J Gastrointest Oncol 2021; 13(11): 1551-1560 [PMID: 34853636 DOI: 10.4251/wjgo.v13.i11.1551] [Reference Citation Analysis]
108 Salem ME, Weinberg BA, Xiu J, El-Deiry WS, Hwang JJ, Gatalica Z, Philip PA, Shields AF, Lenz HJ, Marshall JL. Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. Oncotarget. 2017;8:86356-86368. [PMID: 29156800 DOI: 10.18632/oncotarget.21169] [Cited by in Crossref: 86] [Cited by in F6Publishing: 78] [Article Influence: 17.2] [Reference Citation Analysis]
109 Mizukami T, Izawa N, Nakajima TE, Sunakawa Y. Targeting EGFR and RAS/RAF Signaling in the Treatment of Metastatic Colorectal Cancer: From Current Treatment Strategies to Future Perspectives. Drugs 2019;79:633-45. [PMID: 30968289 DOI: 10.1007/s40265-019-01113-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
110 Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, Pucciarini A, Bigerna B, Pacini R, Wells VA, Sportoletti P, Pettirossi V, Mannucci R, Elliott O, Liso A, Ambrosetti A, Pulsoni A, Forconi F, Trentin L, Semenzato G, Inghirami G, Capponi M, Di Raimondo F, Patti C, Arcaini L, Musto P, Pileri S, Haferlach C, Schnittger S, Pizzolo G, Foà R, Farinelli L, Haferlach T, Pasqualucci L, Rabadan R, Falini B. BRAF mutations in hairy-cell leukemia. N Engl J Med 2011;364:2305-15. [PMID: 21663470 DOI: 10.1056/NEJMoa1014209] [Cited by in Crossref: 700] [Cited by in F6Publishing: 276] [Article Influence: 63.6] [Reference Citation Analysis]
111 Duan J, Yang Y, Yin L, Zhang X, Tang Y, Zhang S, Gong H, Xiao M, Li M, Li Q, Li X, Yang L, Fan Q, Wang Y. Preliminary Study on the Identification of BRAFV600E Mutation in Colorectal Cancer by Near-Infrared Spectroscopy. Onco Targets Ther 2020;13:13077-85. [PMID: 33376356 DOI: 10.2147/OTT.S287814] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
112 Zhang Y, Dong J, Shi R, Feng L, Li Y, Cheng C, Zhang L, Song B, Bi Y, Huang H, Kong P, Guo J, Liu J. Mps1 is associated with the BRAFV600E mutation and predicts poor outcome in patients with colorectal cancer. Oncol Lett 2019;17:2809-17. [PMID: 30854056 DOI: 10.3892/ol.2019.9924] [Reference Citation Analysis]
113 Abancens M, Bustos V, Harvey H, McBryan J, Harvey BJ. Sexual Dimorphism in Colon Cancer. Front Oncol 2020;10:607909. [PMID: 33363037 DOI: 10.3389/fonc.2020.607909] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
114 Johnson B, Loree JM, Jacome AA, Mendis S, Syed M, Morris Ii VK, Parseghian CM, Dasari A, Pant S, Raymond VM, Vilar E, Overman M, Kee B, Eng C, Raghav K, Kopetz S. Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer. JCO Precis Oncol 2019;3:PO. [PMID: 32914034 DOI: 10.1200/PO.19.00102] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
115 Tung JK, Neishaboori N, Haraldsdottir S, Suarez CJ. An amino-terminal BRAF deletion accounting for acquired resistance to RAF/EGFR inhibition in colorectal cancer. Cold Spring Harb Mol Case Stud 2020;6:a005140. [PMID: 32669268 DOI: 10.1101/mcs.a005140] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
116 Dizdar L, Werner TA, Drusenheimer JC, Möhlendick B, Raba K, Boeck I, Anlauf M, Schott M, Göring W, Esposito I, Stoecklein NH, Knoefel WT, Krieg A. BRAFV600E mutation: A promising target in colorectal neuroendocrine carcinoma. Int J Cancer 2019;144:1379-90. [PMID: 30144031 DOI: 10.1002/ijc.31828] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
117 Loupakis F, Moretto R, Aprile G, Muntoni M, Cremolini C, Iacono D, Casagrande M, Ferrari L, Salvatore L, Schirripa M, Rossini D, De Maglio G, Fasola G, Calvetti L, Pilotto S, Carbognin L, Fontanini G, Tortora G, Falcone A, Sperduti I, Bria E. Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer. Br J Cancer. 2016;114:30-36. [PMID: 26575603 DOI: 10.1038/bjc.2015.399] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 4.3] [Reference Citation Analysis]
118 Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, Hamid O, Messersmith WA, Daud A, Kurzrock R, Pierobon M, Sun P, Cunningham E, Little S, Orford K, Motwani M, Bai Y, Patel K, Venook AP, Kopetz S. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. J Clin Oncol. 2015;33:4023-4031. [PMID: 26392102 DOI: 10.1200/jco.2015.63.2471] [Cited by in Crossref: 263] [Cited by in F6Publishing: 166] [Article Influence: 37.6] [Reference Citation Analysis]
119 Robert G, Jullian V, Jacquel A, Ginet C, Dufies M, Torino S, Pottier A, Peyrade F, Tartare-Deckert S, Bourdy G, Deharo E, Auberger P. Simalikalactone E (SkE), a new weapon in the armamentarium of drugs targeting cancers that exhibit constitutive activation of the ERK pathway. Oncotarget 2012;3:1688-99. [PMID: 23518796 DOI: 10.18632/oncotarget.791] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
120 Patel GS, Karapetis CS. Personalized treatment for advanced colorectal cancer: KRAS and beyond. Cancer Manag Res. 2013;5:387-400. [PMID: 24294007 DOI: 10.2147/cmar.s35025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
121 Semira C, Wong H, Field K, Lee M, Lee B, Nott L, Shapiro J, Wong R, Tie J, Tran B, Richardson G, Zimet A, Lipton L, Tamjid B, Burge M, Ma B, Johns J, Harold M, Gibbs P. Chemotherapy and biologic use in the routine management of metastatic colorectal cancer in Australia: is clinical practice following the evidence? Intern Med J 2019;49:446-54. [DOI: 10.1111/imj.14115] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
122 Morris VK. Systemic Therapy in BRAF V600E-Mutant Metastatic Colorectal Cancer: Recent Advances and Future Strategies. Curr Colorectal Cancer Rep. 2019;15:53-60. [PMID: 31762713 DOI: 10.1007/s11888-019-00429-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
123 Vacante M, Borzì AM, Basile F, Biondi A. Biomarkers in colorectal cancer: Current clinical utility and future perspectives. World J Clin Cases 2018; 6(15): 869-881 [PMID: 30568941 DOI: 10.12998/wjcc.v6.i15.869] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 52] [Article Influence: 14.0] [Reference Citation Analysis]
124 Wong H, Gibbs P. Does Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer Really Save Lives? JCO 2013;31:511-2. [DOI: 10.1200/jco.2012.45.7770] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
125 Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. J Pathol. 2014;232:199-209. [PMID: 24122236 DOI: 10.1002/path.4287] [Cited by in Crossref: 784] [Cited by in F6Publishing: 739] [Article Influence: 98.0] [Reference Citation Analysis]
126 Prasanna T, Karapetis CS, Roder D, Tie J, Padbury R, Price T, Wong R, Shapiro J, Nott L, Lee M, Chua YJ, Craft P, Piantadosi C, Sorich M, Gibbs P, Yip D. The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern. Acta Oncol. 2018;57:1438-1444. [PMID: 30035653 DOI: 10.1080/0284186x.2018.1487581] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 7.8] [Reference Citation Analysis]
127 Nakayama I, Shinozaki E, Matsushima T, Wakatsuki T, Ogura M, Ichimura T, Ozaka M, Takahari D, Suenaga M, Chin K, Mizunuma N, Yamaguchi K. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients. BMC Cancer 2017;17:38. [PMID: 28068936 DOI: 10.1186/s12885-016-2994-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
128 Hocking CM, Townsend AR, Price TJ. Panitumumab in metastatic colorectal cancer. Expert Review of Anticancer Therapy 2014;13:781-93. [DOI: 10.1586/14737140.2013.811064] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
129 Cremolini C, Pietrantonio F, Tomasello G, Dadduzio V, Moretto R, Morano F, Schirripa M, Antoniotti C, Fucà G, Bergamo F, Rossini D, Nichetti F, Ziampiri S, Ghidini M, Marmorino F, Prisciandaro M, Falcone A, De Braud F, Loupakis F, Lonardi S. Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study. ESMO Open 2017;2:e000241. [PMID: 29209533 DOI: 10.1136/esmoopen-2017-000241] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
130 Chen D, Zhang LQ, Huang JF, Liu K, Chuai ZR, Yang Z, Wang YX, Shi DC, Liu Q, Huang Q. BRAF mutations in patients with non-small cell lung cancer: a systematic review and meta-analysis. PLoS One. 2014;9:e101354. [PMID: 24979348 DOI: 10.1371/journal.pone.0101354] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 6.4] [Reference Citation Analysis]
131 Thiel A, Heinonen M, Kantonen J, Gylling A, Lahtinen L, Korhonen M, Kytölä S, Mecklin J, Orpana A, Peltomäki P, Ristimäki A. BRAF mutation in sporadic colorectal cancer and Lynch syndrome. Virchows Arch 2013;463:613-21. [DOI: 10.1007/s00428-013-1470-9] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 5.4] [Reference Citation Analysis]
132 Warsinggih, Liliyanto, Marhamah, Kusuma MI, Uwuratuw JA, Syarifuddin E, Faruk M. Relationship between BRAF V600E and KRAS mutations in stool for identifying colorectal cancer: A cross-sectional study. Ann Med Surg (Lond) 2020;60:121-5. [PMID: 33145020 DOI: 10.1016/j.amsu.2020.10.027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
133 Oddo D, Sennott EM, Barault L, Valtorta E, Arena S, Cassingena A, Filiciotto G, Marzolla G, Elez E, van Geel RM, Bartolini A, Crisafulli G, Boscaro V, Godfrey JT, Buscarino M, Cancelliere C, Linnebacher M, Corti G, Truini M, Siravegna G, Grasselli J, Gallicchio M, Bernards R, Schellens JH, Tabernero J, Engelman JA, Sartore-Bianchi A, Bardelli A, Siena S, Corcoran RB, Di Nicolantonio F. Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer. Cancer Res 2016;76:4504-15. [PMID: 27312529 DOI: 10.1158/0008-5472.CAN-16-0396] [Cited by in Crossref: 57] [Cited by in F6Publishing: 44] [Article Influence: 9.5] [Reference Citation Analysis]
134 Ye LF, Ji XM, Ren C, Wang ZQ, Lin CP, Chen DL, Cai YQ, Jin Y, Qiu MZ, Du ZM, Xi SY, Zhang DS, Wang F, Wang FH, Xu RH, Li YH, Wang DS. The Prognostic Value of Locoregional Interventions for BRAF V600E Metastatic Colorectal Cancer: A Retrospective Cohort Analysis. Biomolecules 2021;11:1268. [PMID: 34572480 DOI: 10.3390/biom11091268] [Reference Citation Analysis]
135 Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Maru D, Morris V, Janku F, Dasari A, Chung W, Issa JP, Gibbs P, James B, Powis G, Nolop KB, Bhattacharya S, Saltz L. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. J Clin Oncol. 2015;33:4032-4038. [PMID: 26460303 DOI: 10.1200/jco.2015.63.2497] [Cited by in Crossref: 374] [Cited by in F6Publishing: 208] [Article Influence: 53.4] [Reference Citation Analysis]
136 Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH, Agarwal A, Maru DM, Sieber O, Desai J. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. 2011;117:4623-4632. [PMID: 21456008 DOI: 10.1002/cncr.26086] [Cited by in Crossref: 411] [Cited by in F6Publishing: 382] [Article Influence: 37.4] [Reference Citation Analysis]
137 Foroughi S, Wong HL, Tie J, Wong R, Lee M, Lee B, Jones I, Skinner I, Burgess AW, Gibbs P. Characteristics and outcomes of participants in colorectal cancer biomarker trials versus a real-world cohort. Acta Oncol 2021;60:482-90. [PMID: 33377792 DOI: 10.1080/0284186X.2020.1862907] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
138 Li ZN, Zhao L, Yu LF, Wei MJ. BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy. Gastroenterol Rep (Oxf) 2020;8:192-205. [PMID: 32665851 DOI: 10.1093/gastro/goaa022] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
139 Matsuoka T, Yashiro M. Precision medicine for gastrointestinal cancer: Recent progress and future perspective. World J Gastrointest Oncol 2020; 12(1): 1-20 [PMID: 31966910 DOI: 10.4251/wjgo.v12.i1.1] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
140 Keil M, Conrad T, Becker M, Keilholz U, Yaspo ML, Lehrach H, Schütte M, Haybaeck J, Hoffmann J. Modeling of Personalized Treatments in Colon Cancer Based on Preclinical Genomic and Drug Sensitivity Data. Cancers (Basel) 2021;13:6018. [PMID: 34885128 DOI: 10.3390/cancers13236018] [Reference Citation Analysis]